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Objectives: Regulatory T cells (Tregs) are frequently functionally impaired in patients
with granulomatosis with polyangiitis (GPA). However, the mechanism underlying their
impaired function is unknown. Here, we hypothesized that Treg dysfunction in GPA is
due to altered microRNA (miRNA) expression.
Methods: RNA isolated from FACS-sorted memory (M) Tregs
(CD4+CD45RO+CD25+CD127−) of 8 healthy controls (HCs) and 8 GPA patients
without treatment was subjected to miRNA microarray analysis. Five differentially
expressed miRNAs were validated in a larger cohort by reverse transcriptase quantitative
polymerase chain reaction (RT-qPCR). An miRNA target gene database search revealed
targets that were tested with RT-qPCR in MTregs from patients and HCs. cAMP levels
were measured using flow cytometry.
Results: Microarray analysis revealed 19 differentially expressed miRNAs, of which
miR-142-3p was confirmed to be significantly upregulated in MTregs from GPA patients
compared to those from HCs (1.9-fold, p = 0.03). In vitro overexpression of miR-142-3p
lowered the suppressive capacity of MTregs (2.1-fold, p = 0.03), and miR-142-3p
expression correlated negatively with the suppressive capacity (rho = −0.446, p =
0.04). Overexpression of miR-142-3p significantly decreased cAMP levels (p = 0.02)
and tended to decrease the mRNA levels of a predicted target gene, adenylate cyclase
9 (ADCY9; p = 0.06). In comparison to those from HCs, MTregs from GPA patients had
lower ADCY9mRNA levels (2-fold, p= 0.008) and produced significantly less cAMP after
stimulation. Importantly, induction of cAMP production in miR-142-3p overexpressed
MTregs by forskolin restored their suppressive function in vitro.
Conclusion: Overexpression of miR-142-3p in MTregs from GPA patients might
cause functional impairment by targeting ADCY9, which leads to the suppression
of cAMP production.
Keywords: ANCA—associated vasculitis, Treg—regulatory T cell, auto immune, microRNA, suppressive function
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INTRODUCTION
Antineutrophil cytoplasmic autoantibody (ANCA)-associated
vasculitides (AAV) constitute a heterogeneous group of
autoimmune syndromes characterized by pauci-immune
necrotizing inflammation of small- to medium-sized blood
vessels (1). These vasculitides of unknown etiology are
predominantly associated with the presence of ANCAs
directed against either proteinase-3 (PR3) or myeloperoxidase
(MPO) (2). Based on the presence of specific ANCAs and
clinical symptoms, AAV can be subdivided into microscopic
polyangiitis (MPA), eosinophilic granulomatosis with
polyangiitis (EGPA) and granulomatosis with polyangiitis
(GPA), which is predominantly associated with the presence of
PR3-ANCAs (1).
Although current immunotherapeutic strategies underscore
the crucial role of B cells in GPA pathogenesis, several
observations support the involvement of T cells in this
disease. The presence of abundant T cell infiltrates in
GPA lesions, persistent T cell activation with imbalances
in circulating CD4+T cell subsets and the induction
of remission by T cell-targeted therapies highlight the
important role of T cell-mediated responses in GPA
(3–9). Similar to those with various other autoimmune
diseases, patients with GPA have impaired regulatory T
cell (Treg) function (10–13). In vitro experiments have
shown that circulating Tregs from GPA patients have a
reduced ability to suppress the proliferation of activated
effector cells (14–16). However, the exact mechanisms that
contribute to the functional impairment of Tregs in GPA are
currently unknown.
microRNAs (miRNAs) are single-stranded, noncoding RNA
molecules of 19–22 nucleotides that regulate gene expression at
the posttranscriptional level by binding complementary regions
in the 3′ UTR of target messenger RNA (mRNA), leading to
the degradation or translational inhibition of target mRNA
(17). In recent years, many studies have identified a large
number of miRNAs involved in the regulation of various T
cell functions (17–19) and differential expression in T cells
and Tregs is associated with T cell-mediated autoimmune
diseases such as systemic lupus erythematosus (SLE), rheumatoid
arthritis (RA), psoriasis and ulcerative colitis (20–24). For
example, reduced upregulation of miRNA-146a after T cell
activation, was observed in patients with RA compared to
healthy controls. This diminished upregulation of miR-146a
facilitated a proinflammatory phenotype of Tregs by increased
levels of STAT1, a direct target of miR-146a (23). To date, it is
unknown whether miRNAs are differentially expressed in Tregs
of GPA patients and whether specific miRNAs are linked to
the observed impaired suppressive function of these Tregs. In
the current study, we hypothesized that differentially expressed
miRNAs underlie the diminished suppressive function of Tregs
in GPA.
Since the expanded Treg population in the peripheral blood
of GPA patients is confined to memory cells (7), we examined the
differential miRNA expression profile in sorted MTregs, effector
memory and naïve T cells from GPA patients.
SUBJECTS AND METHODS
Subjects
Patients diagnosed with GPA based on the Chapel Hill Consensus
classification and were PR3-ANCA positive were recruited
(25). All included patients were in clinical remission with a
Birmingham Vasculitis Activity Score (BVAS) of zero (26).
The inception cohort, containing eight patients with GPA
and eight age- and sex-matched healthy controls, was selected
for microarray-based miRNA expression profiling. Twenty-
three patients and 23 healthy controls, including the patients
selected for microarray analysis, were included in the validation
cohort. Patient characteristics are shown in Table 1. This
study was approved by the local Medical Ethics Committee
(METC2010/057), and informed consent was obtained from all
participants. The study was performed in accordance with the
declaration of Helsinki.
Sample Preparation and Treg Cell Sorting
Peripheral blood was collected, and peripheral blood
mononuclear cells (PBMCs) were isolated using density-
gradient centrifugation on Lymphoprep (Axis-Shield, Oslo,
Norway). Isolated PBMCs were stained with anti-CD8-
AF700 (Affymetrix, San Diego, CA, USA); anti-CD4-eF450
(Thermo Fisher Scientific, Breda, The Netherlands); and
anti-CD45RO-FITC, anti-CD127-AF647, anti-CD25-PE,
and anti-CCR7-PE-CY7 (BD Biosciences, Breda, The
Netherlands) and sorted using FACS (MoFlo Astrios,
Beckman Coulter, Woerden, The Netherlands). Memory
Tregs (MTregs) (CD4+CD8−CD45RO+CD127−CD25high),
naïve T (TNAÏVE) cells (CD4
+CD8−CD45RO−CCR7+), and
effector memory T (TEM) cells (CD4+CD8−CD45RO+CCR7−)
were sorted (Figure 1A).
The purity of the sorted populations, was >95% for all
samples. Samples were subsequently lysed using QIAzol lysis
reagent (Qiagen, Venlo, The Netherlands) and stored at−80◦C.
RNA Isolation
Total RNAwas extracted using the miRNeasyMicro Kit (Qiagen)
according to the manufacturer’s instructions. After isolation,
RNA samples were further purified using Micro Bio-Spin
columns (Bio-Rad, Veenendaal, The Netherlands).
miRNA Microarray
Total RNA was hybridized to an Agilent G3 unrestricted
miRNA microarray with an 8 × 60K format (G4872-070156,
based on miRBase Release 21.0) and scanned using an
Agilent scanner according to the manufacturer’s instructions
(Agilent Technologies, Santa Clara, CA, USA). Array image
data were extracted using Agilent Feature Extraction software
(version 10.7). Data analysis was performed using GeneSpring
software version 14.8. Raw data were normalized using the 95-
percentile shift method. Control probes were excluded from
the analysis. miRNAs with a signal intensity that reached
>40% of the maximum signal in all samples of at least
1 cell type were considered for statistical analysis (two-
way ANOVA with multiple sampling correction). A total
of 19 miRNAs were differentially expressed, of which five
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TABLE 1 | Patient characteristics.
miRNA inception cohort miRNA validation cohort cAMP cohort
Patients in
remission
Healthy controls Patients in
remission




Number (n) 8 8 23 23 10 10
Median age (years) 55.7 (49.6–62.5) 53.9 (46.0–58.5) 53.1 (46.0–62.5) 54.0 (46.3–64.5) 57.5 (56.0–64.5) 58.6 (53.1–63.3)
Male, n (%) 5 (62.5%) 5 (62.5%) 11 (47.8%) 13 (56.5%) 4 (40%) 4 (40%)
Disease Characteristics
BVAS 0 – 0 – 0 –
Time after diagnosis (months) 168 (102–216) – 149 (82–201) – –
Patients with relapse, n (%) 5 (62.5%) – 12 (52.2%) – 6 (60%) –
Number of relapses, n 1 (0–3) – 1 (0–2) – 2 (0–3) –
Laboratory findings
PR3-ANCA titer 40 (0–80) – 40 (0–80) – 80 (0–160) –
Leucocytes (×109/l) 6.0 (4.8–7.0) – 6.0 (5.3–6.9) – 6.3 (5.1–7.4) –
CRP (mg/l) 3 (1–6) – 3 (1–4) – 3 (2–6) –




FIGURE 1 | Frequencies of CD4+T cells and CD4+T cell subsets in healthy controls (HC) and GPA patients in remission (GPA). Representative FACS plots of sorted
CD4+T cell subsets (A). CD4+T cell frequencies were lower in GPA than in HC (B). Within the CD4+T cell population, no differences were observed in naïve T (TNAVE)
cells (CD4+CD45RO−CCR7−) (C), whereas the MTreg (CD4
+CD127−CD25HighCD45RO+) frequency was higher in GPA than in HC (D). A significantly higher
frequency of CD4+T effector memory (TEM) cells (CD4
+CD45RO+CCR7−) was observed in GPA than in HC (E). **P = 0.01–0.001, ***P ≤ 0.001.
miRNAs were selected for validation. This selection of the
miRNAs for validation was based on availability of commercial
assays (miR-6068, miR-4516 were not available at time of
validation) and expression levels above detection limits of
qPCR (miR-148a-3p, miR-27b-3p, miR-361-3p were expressed
at low levels). The remaining 14 miRNAs were ranked based
on both expression level and fold change between patients
and healthy controls, and five miRNAs were selected for
further validation.
RT-qPCR
miRNA and gene expression levels were determined by RT-
qPCR. For miRNA assays, total RNA was reverse transcribed
using the TaqMan MicroRNA Reverse Transcription kit in a
multiplex RT approach in combination with TaqMan MicroRNA
Assays (both Thermo Fisher Scientific) for hsa-Let-7g-5p
(#002282), hsa-miR-20a-5p (#000580), hsa-miR-26a-5p
(#000405), hsa-miR-142-3p (#000464), hsa-miR-146b-5p
(#001097), and RNU48 (#001006).
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For gene expression assays, random hexamer reverse
transcription of total RNA was performed using the High-
Capacity cDNA Reverse Transcription Kit (Thermo Fisher
Scientific) according to the manufacturer’s instructions.
qPCR was performed on a ViiA7 Real-Time PCR System
(Thermo Fisher Scientific) using qPCR MasterMix Plus
(Eurogentec, Liege, Belgium) and TaqMan MicroRNA Assays for
the miRs and TaqMan Gene Assays for human adenylate cyclase
9 (ADCY9) (Hs00181599_m1) and GAPDH (Hs02786624_g1)
(Thermo Fisher Scientific). Mean threshold cycle (Ct) values for
all genes were quantified using QuantStudio Real-Time PCR
software (Thermo Fisher Scientific). The expression levels of
miRs relative to RNU48 and of ADCY9 relative to GAPDH were
calculated using the 2−1Ct method.
miRNA Transfection and Suppression
Assay
For the suppression assay, healthy control MTregs and T
responder (TRESP) cells (CD4+CD127+CD25−) were sorted.
Sorted MTregs were expanded using anti-CD3/CD28 Dynabeads
and 200 International Units (IU)/ml IL-2 (Peprotech, Rocky
Hill, USA) according to the manufacturer’s protocol (Thermo
Fisher Scientific) in RPMI1640 (Lonza, Breda, The Netherlands)
supplemented with 10% human pooled serum (HPS) and
60µg/ml gentamycin sulfate (Lonza).
Expanded MTregs were transiently transfected with miRNA
mimic scrambled control (SCR) or miRNA mimic hsa-miR-
142-3p (MIM-142-3p) (Thermo Fisher Scientific) using the
Nucleofector I system and the Human T cell Nucleofector
kit (Lonza) according to the manufacturers’ instructions. The
Nucleofector program T-23 was used to transfect 50 nM mimic
per 1.106 cells. Transfected MTregs were incubated overnight.
MTregs were harvested and live cells were sorted on aMoFlo XDP
cell sorter (Beckman Coulter).
For the suppression assay, TRESP (CD4+CD25−) cells were
labeled with proliferation dye eFluor670 (1µM; Thermo Fisher
Scientific). TRESP cells and MTregs were cocultured at a 2:1
ratio and stimulated using anti-CD3/CD28 Dynabeads. After
3 days, the cells were stained with a viability dye, and TRESP
cell proliferation was analyzed on a BD LSRII flow cytometer.
For cyclic adenosine monophosphate (cAMP) measurements
(see below), transfected MTregs were stimulated for 2 days with
anti-CD3/CD28 Dynabeads.
Stability of miRNA-142-3p Expression
To assess miR-142-3p expression levels in MTregs after
activation, sorted cells were stimulated for 24, 48, or
72 h with anti-CD3/CD28 Dynabeads and harvested
for RNA isolation. Moreover, miR-142-3p expression
levels in sorted unstimulated MTregs and naïve (N)Tregs
(CD4+CD8−CD45RO−CD127−CD25+) were determined.
cAMP Production and FoxP3 Expression
PBMCs from 10 PR3-positive GPA patients and 10 matched
HCs (cAMP cohort, Table 1) were stimulated with anti-
CD3/anti-CD28 Dynabeads. Intracellular cAMP levels in MTregs
were assessed by flow cytometry. First, cells were fixed and
permeabilized using a FoxP3 Fixation and Permeabilization kit
(eBioscience) according to the manufacturer’s protocol. Next,
cells were stained with an unconjugated mouse-anti-cAMP
antibody followed by a secondary goat-anti-mouse-PE antibody
(Abcam, Cambridge, UK). MTregs were stained using anti-
CD3-PerCP, anti-CD4-eFluor450, anti-CD45RO-FITC, and anti-
FoxP3-APC (eBioscience) and analyzed on a BD LSRII flow
cytometer (Becton-Dickinson). Data were analyzed using Kaluza
software (V1.5a, Beckman Coulter), and MTregs were defined
as CD3+CD4+CD45RO+FoxP3high.
Forskolin Treatment of miR-142-3p
Overexpressed MTregs
In order to assess if cAMP elevating agent could restore
Treg function, miR-142-3p overexpressed MTregs were cultured
in the presence and absence of 0.1µM Forskolin (Sigma
Aldrich, Saint Louis, Missouri, USA). Next, intracellular cAMP
levels and suppressive capacity were assessed at 48 and
72 h, respectively.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism
version 7 for Windows (GraphPad Software, San Diego,
California, USA). Data were tested for normality using the
D’Agostino-Pearson normality test; normally distributed data
TABLE 2 | Differentially expressed miRNAs in MTregs.
HC GPA Fold change p-value
ha-miR-142-3p 38.83 62.86 1.62 0.038
ha-let-7g-5p 21.40 32.84 1.53 0.038
hsa-miR-26a-5p 8.07 15.24 1.89 0.048
hsa-miR-20a-5p 5.18 8.15 1.57 0.044
hsa-miR-146b-5p 2.26 5.95 2.63 0.016
hsa-miR-4516 19.53 10.39 0.53 0.038
hsa-let-7f-5p 10.79 17.30 1.60 0.038
hsa-let-7a-5p 9.96 15.38 1.54 0.038
hsa-miR-19b-3p 5.35 10.05 1.88 0.048
hsa-miR-103a-3p 4.32 7.07 1.64 0.049
hsa-miR-107 3.69 6.17 1.67 0.049
hsa-let-7d-5p 2.18 3.29 1.51 0.049
hsa-miR-17-5p 2.03 3.32 1.64 0.048
hsa-miR-6068 1.96 1.31 0.67 0.048
hsa-miR-20b-5p 1.33 2.33 1.76 0.044
hsa-miR-30e-5p 1.28 2.94 2.29 0.048
hsa-miR-361-3p 0.42 0.79 1.86 0.048
hsa-miR-27b-3p 0.14 0.54 3.76 0.046
hsa-miR-148a-3p 0.13 0.47 3.57 0.048
miRNA which are increased in expression in GPA are highlighted in red, with reduced
expression in GPA in blue.
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were analyzed for significant differences by Student’s T-test. A p-
value <0.05 was considered significant. As miRNA levels, cAMP
levels and the cAMP total area under the curve (AUC) were
not normally distributed, differences between the groups were
analyzed using the Mann–Whitney test.
RESULTS
GPA Patients Have a Higher Percentage of
Circulating MTregs
To explore differences in the distribution of circulating
CD4+T cell subsets, we determined the frequency of MTregs
(CD4+CD25HighCD45RO+), TEM (CD4+CD45RO+CCR7−),
and TNAÏVE (CD4
+CD45RO−CCR7+) in GPA patients and
healthy controls. Patients had a significantly lower percentage of
circulating CD4+T cells than did healthy controls (35.0 vs. 50.2%;
Figure 1B). Additionally, the percentage of circulating MTregs
was significantly increased in patients compared to healthy
controls (1.7 vs. 0.7%; Figure 1D). The percentage of circulating
TEM was significantly higher in patients than in healthy
controls (45.6 vs. 25.7%; Figure 1E). No significant differences
were found in the relative frequency of TNAÏVE (13.3 vs.
9.9%; Figure 1C).
Increased miR-142-3p Levels in GPA
MTregs
We compared the miRNA expression profiles of MTregs, TEM,
and TNAÏVE from healthy controls and GPA patients. Nineteen
miRNAs were found to be differentially expressed, of which
17 were significantly upregulated and two were significantly
downregulated in GPA patients (Table 2, Supplemental Table 1).
Based on a combination of expression levels, fold change and the
commercial availability of assays, the top-5 miRs were selected
for validation (hsa-let-7g-5p, hsa-miR-20a-5p, hsa-miR-26a-5p,
hsa-miR-142-3p, and hsa-miR-146b-5p).
miR-142-3p expression levels were significantly higher in
MTregs from patients than in those from healthy controls (1.9-
fold; Figure 2A). No differences were found in the expression
of the other selected miRs in MTregs or in the expression
of all five miRs in TNAÏVE and TEM in the validation cohort
(Supplemental Figure 1).
Interestingly, miR-142-3p expression was significantly
lower in freshly isolated MTregs than in naïve (N)Tregs
(CD4+CD45RO−CD25+) from healthy controls (2.3-fold;
Figure 2B) than in TNAÏVE and TEM cells from both healthy
controls and patients (Figure 2C). The relatively lowmiR-142-3p
expression levels in MTregs might indicate that this miRNA is
tightly regulated and low levels are necessary for efficient Treg
function. Moreover, miR-142-3p levels in MTregs and NTregs
from healthy controls tended to be lower after 48 h of activation
(p = 0.11) and were significantly downregulated after 72 h of
stimulation (2-fold, p= 0.006; Figure 2D).
Patient-related variables, such as age (p= 0.37), sex (p= 0.19),
ANCA titer (p = 0.67), or immunosuppressive treatment, were
not associated with miR-142-3p levels.
Overexpression of miR-142-3p Reduces
the Suppressive Capacity of MTregs,
Potentially via ADCY9
To determine whether increased levels of miR-142-3p influence
Treg function, MTregs from healthy controls were transfected
with miR-142-3p mimic (MIM-142-3p) or scrambled control
(SCR), and their ability to suppress TRESP cell proliferation was
measured in vitro.
miR-142-3p levels were significantly increased in MTregs
transfected with MIM-142-3p compared to those transfected
with SCR (2.4-fold, p = 0.03; Figure 3C). Both SCR- and
MIM-142-3p-transfected Tregs were able to suppress TRESP cell
proliferation (Figures 3A,B). However, the suppressive capacity
was significantly reduced in MIM-142-3p-transfected Tregs
(2.1-fold, p = 0.03; Figure 3D). Importantly, we observed that
miR-142-3p levels correlated negatively with the degree of
suppression (rho=−0.446, p= 0.04; Figure 3E).
To explain the observed reduced suppressive capacity caused
by miR-142-3p overexpression in Tregs, we searched for
targets of miR-142-3p. Huang et al. reported that miR-142-
3p overexpression in mouse Tregs reduces their suppressive
capacity by targeting adenylate cyclase 9 (ADCY9). TargetScan
version 7.1 predicted that ADCY9 is a highly conserved target
of miR-142-3p, and human ADCY9 was confirmed as potential
target (miRMap, TargetMiner). ADCY9 is a membrane-bound
enzyme that catalyzes the conversion of adenosine triphosphate
(ATP) into cAMP, which initiates suppression after delivery
into effector T cells. Here, we hypothesized that miR-142-3p
overexpression diminishes the Treg-mediated downregulation of
ADCY9-induced cAMP production.
To assess whether miR-142-3p expression in Tregs
influences ADCY9 and cAMP levels, ADCY9 and cAMP
levels were measured after MIM-142-3p or SCR transfection.
The overexpression of miR-142-3p was associated with
decreased ADCY9 mRNA levels (1.3-fold, p = 0.06; Figure 3F).
Importantly, miR-142-3p levels were significantly negatively
correlated with ADCY9 mRNA levels (rho = −0.890, p = 0.001;
Figure 3G). Additionally, after 48 h of stimulation, miR-142-3p
overexpression led to significantly lower cAMP levels (1.4-fold, p
= 0.02; Figure 3H).
Decreased ADCY9 mRNA and cAMP
Levels in MTregs From GPA Patients
To provide further support for the role of ADCY9 in GPA,
we assessed ADCY9 mRNA levels in MTregs from GPA
patients and healthy controls. ADCY9 mRNA levels were
significantly lower in patients than in healthy controls (3.3
vs. 1.8, p = 0.008; Figure 4A). However, no correlation
between miR-142-3p expression and ADCY9 mRNA levels was
found (Figure 4B).
As ADCY9 mRNA levels were reduced in GPA, we next
investigated whether this affected cAMP levels in stimulated
MTregs from GPA patients. cAMP levels were comparable at
baseline but were significantly higher in MTregs from healthy
controls after 48 h of stimulation (MFI: 149 vs. 121, p = 0.042;
data not shown). Moreover, total cAMP at 48 h after stimulation
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FIGURE 2 | miR-142-3p is overexpressed in MTregs from GPA patients in remission and is differentially regulated in CD4
+T cell subsets. miR-142-3p levels were
significantly higher in MTregs from GPA patients (GPA) than in those from healthy controls (HC) (A). miR-142-3p levels were significantly lower in MTregs than in NTregs
(B) and in CD4+TNAVE and CD4
+TEM cells from HC (circles) and GPA patients (squares) (C). Stimulation of MTregs and NTregs with anti-CD3-CD28 Dynabeads led
to significantly lower miR-142-3p levels over time (n = 5) (D). *P = 0.05–0.01, **P = 0.01–0.001.
was significantly higher in MTregs from healthy controls than in
those from GPA patients (ratio: 2.4 vs. 1.9, p = 0.03; Figure 4C).
In addition, the total amount of cAMP produced over 48 h
of stimulation, as determined by the AUC, was significantly
higher in MTregs of healthy controls (34.2 vs. 22.3, p = 0.003;
Figure 4D). In line with cAMP, FoxP3 levels were significantly
higher in MTregs from healthy controls than in those from
patients (MFI: 9.6 vs. 8.5, p = 0.05; Figure 4E) and correlated
strongly with cAMP levels (p = 0.003, rho = 0.600; Figure 4F)
and total cAMP produced (p= 0.003, rho= 0.577).
cAMP Elevating Therapy Restores MTreg
Function in vitro
We next aimed to restore the suppressive function of miR-
142-3p overexpressed MTreg derived from healthy controls,
by enhancing their intracellular cAMP levels in vitro. To
this end, miR-142-3p overexpressed MTregs were treated with
cAMP elevating agent, Forskolin. Indeed, upon treatment with
Forskolin, intracellular cAMP levels was significantly increased
in miR-142-3p transfected MTregs (Figure 5B).
Importantly, Forskolin treatment tended to restore the
suppressive function of miR-142-3p overexpressed MTregs in
comparison to the non-transfected control cells (p = 0.06). In
addition, no direct effect of Forskolin on TRESP proliferation
was seen (Figures 5A,C). These results offer further proof
that miR-142-3p overexpression inhibits cAMP/ADCY9
suppression and that the reduced Treg suppression,
induced by miR-142-3p overexpression, could be restored
by Forskolin.
DISCUSSION
In the present study, we hypothesized that miRNA dysregulation
could underlie the reduced MTreg function in patients with
GPA. We found a significant increase in the miR-142-3p
expression level in MTregs from GPA patients. In vitro
overexpression of miR-142-3p in healthy control MTregs was
associated with lower ADCY9 mRNA levels, reduced cAMP
levels and a reduction in the suppressive capacity of Tregs.
In addition, we found lower ADCY9 mRNA and cAMP levels
in MTregs from GPA patients than in those from healthy
controls. Based on these findings, we conclude that miR-
142-3p overexpression can decrease Treg function and may
underlie the functional impairment seen in Tregs of patients
with GPA. This impaired Treg function could be explained
by the ADCY9-dependent downregulation of cAMP, a crucial
axis that is prominently involved in the suppressive function of
Tregs (Figure 6).
Numerous studies in autoimmune diseases, such as SLE,
RA and psoriasis, have reported impaired Treg function (10–
13). Additionally, the functional impairment of Tregs is well-
established in GPA (14–16). However, the exact mechanisms
underlying this reduced Treg suppressive capacity are not
fully understood.
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FIGURE 3 | Overexpression of miR-142-3p reduces the suppressive capacity of MTregs in vitro. MTregs were transfected with scrambled (SCR) or miR-142-3p mimic
(MIM-142-3p). Live MTregs were sorted and cocultured with responder T (TRESP) cells; after 48 h of stimulation, TRESP cell proliferation was determined (A,B).
Transfection with MIM-142-3p significantly increased miR-142-3p levels (C) and reduced the suppressive capacity of MTregs (D). miR-142-3p levels correlated
negatively with the suppressive capacity (E). Transfection with MIM-142-3p further decreased ADCY9 mRNA levels (F) and correlated negatively with miR-142-3p
levels (G). Additionally, cAMP levels were significantly lower in MIM-142-3p-transfected MTregs (red) than in SCR-transfected MTregs (black) (H). *p = 0.05–0.01.
Tregs can suppress immune responses in several distinct
manners, of which metabolic disruption via the transfer of
cAMP to effector cells or the production of extracellular
adenosine is considered a highly potent mechanism of
suppression by Tregs (27–29). Klein et al. showed that
blocking adenylyl cyclase (AC) activity reduced intracellular
cAMP levels and the suppressive capacity of Tregs in vitro
(30). This finding was supported by blocking AC activity
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FIGURE 4 | MTreg ADCY9 mRNA and cAMP levels are reduced in patients with GPA. ADCY9 mRNA levels were significantly lower in patients in remission (GPA) (A),
but mRNA levels of ADCY9 did not correlate with miR-142-3p expression (B). In the cAMP cohort, cAMP levels were measured in MTregs upon stimulation. cAMP
levels in MTregs were higher in healthy controls (HC) after 48 h stimulation (n = 10) than in GPA (n = 10) (C), and total cAMP production was significantly higher in HC
than in GPA (D). Besides cAMP, FoxP3 expression was also higher in HC after stimulation (E) and FoxP3 levels correlated with cAMP (F). *p = 0.05–0.01, **p =
0.01–0.001.
in Tregs in vivo, which led to the inability to suppress
graft-vs.-host disease in mice (30). Further evidence was
provided by Bopp and coworkers, who demonstrated that
blocking phosphodiesterase 4 (PDE4), a cAMP-degrading
enzyme, in an allergic asthma mouse model led to increased
cAMP levels and reduced airway hyperresponsiveness and
inflammation (31).
Recent studies have shown that miR-142-3p can directly target
ADCY9 mRNA and that its overexpression significantly reduces
ADCY9 protein levels in mouse CD4+CD25+ Tregs (32, 33). In
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FIGURE 5 | cAMP elevating agent Forskolin increases Treg function via the increase of cAMP. As proof of principle we tried to restore Treg function after miR-142-3p
overexpression using cAMP elevating agent Forskolin. MTregs were transfected with scrambled (SCR) or miR-142-3p mimic (MIM-142-3p). Live MTregs were sorted
and cocultured with responder T (TRESP) cells; after 48 h of stimulation, TRESP cell proliferation was determined (A). Upon treatment with Forskolin, cAMP levels
increased significantly (B). Moreover, forskolin treatment tended to restore suppressive function in miR-142-3p overexpressed MTregs (C).*p = 0.05–0.01, **p =
0.01–0.001.
line with these results, we found that miR-142-3p overexpression
in Tregs significantly reduced cAMP levels, which, in turn,
led to a reduction in Treg-mediated suppression. Additionally,
we found a significant trend toward a negative correlation
between miR-142-3p levels and the suppressive capacity of Tregs,
indicating that miR-142-3p influences Treg function via ADCY9
and cAMP.
Additionally, as proof of principle, cAMP elevating agent
Forskolin was used to treat miR-142-3p overexpressed
MTregs. We showed that Forskolin was able to restore
cAMP levels of miR-142-3p overexpressed MTregs. Not
only were cAMP levels restored, Forskolin also improved
Treg mediated suppression. Our results are in line with
a previous study which showed a significant increase in
Treg function after treatment with cholera toxin, another
cAMP elevating agent (34). Low dose Forskolin did not
affect TRESP alone. All in all, these data further supports
the functional impact of miR-142-3p overexpression on
ADCY9/cAMP mediated suppression and the ability to restore
this functional deficit.
To date, the exact mechanism of miR-142-3p regulation
is not fully understood and could be linked to intrinsic or
extrinsic factors. Previously, a link between FoxP3 and miR-
142-3p expression was identified. Overexpression of FoxP3 in
CD4+CD25−T cells led to a substantial decrease in miR-142-
3p levels (33). In accordance with this finding, we found that
miR-142-3p expression was lower in MTregs than in other
FoxP3-negative CD4+T cell subsets. Moreover, we showed that
upon activation of MTregs, FoxP3 expression and cAMP levels
increased, whereas miR-142-3p levels decreased significantly.
Collectively, these data indicate that FoxP3 is an important factor
in the regulation of miR-142-3p expression in MTregs.
Previous studies have shown that Tregs can express different
FoxP3 isoforms, of which the most common are FoxP3 full
length, FoxP3 lacking exon 2 (FoxP31E2), and FoxP3 lacking
exons 2 and 7 (FoxP31E21E7) (35). The expression of FoxP3
isoforms other than the full-length form is associated with
diminished Treg function (36). It has been reported that the
proportion of FoxP31E2-expressing Tregs is increased in AAV,
including GPA, and correlates negatively with the degree of
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FIGURE 6 | Proposed model of miR-142-3p, which targets the adenylyl cyclase 9/cAMP-mediated suppression of Tregs. We propose that miR-142-3p
overexpression in GPA patients reduces ADCY9 levels, which leads to less conversion of ATP to cAMP upon stimulation. cAMP can be transferred to effector cells via
a Gap junction (GJ). Upon transfection, cAMP levels in effector cells increase, which induces metabolic disruption and inhibits IL-2 production and cell proliferation.
Increased miR-142-3p levels therefore decrease Treg function.
suppression (14). Since we demonstrate here that the suppressive
capacity of Tregs is associated with miR-142-3p expression, one
could speculate that FoxP31E2-expressing Tregs have reduced
suppressive capacity because of their diminished ability to
suppress miR-142-3p expression. Clearly, further studies are
required to investigate the potential links among FoxP3 isoform
expression, miR-142-3p, and Treg function.
In addition to FoxP3 expression, immunosuppressive
medication could also influence miR expression levels. A recent
study showed that in vitro treatment of CD4+T cells with
mycophenolate mofetil induced miR-142-3p expression (37).
We did not detect a pronounced effect of treatment on miR-
142-3p expression levels in our study samples. However, most
of the included patients had not received immunosuppressive
treatment at the time of sampling, so it would be difficult for us
to detect such effects.
This study was cross-sectional; it would be interesting to
study miR-142-3p levels in T cells from GPA patients in a
longitudinal manner. Moreover, a previous study showed that
some patients have normal Treg function in vitro (15). We also
found that miR-142-3p levels were not higher in all patients
than in healthy controls. Previous studies have also reported
that not in all GPA patients Treg function is diminished. In our
cohorts, we previously found that ∼60–70% of GPA patients
have Tregs with diminished suppressive function (15). This
is in line with our finding that miR-142-3p is only increased
in a subset of GPA patients. Additionally, it is conceivable
that Tregs have additional defects not mediated by the
miR-142-3p-ADCY9-cAMP axis.
In conclusion, increased expression of miR-142-3p in MTregs
from patients with GPA might underlie their functional
impairment bymodulating ADCY9-mediated cAMPproduction.
Our results suggest that therapeutic interventions aiming to
restore miR-142-3p and cAMP levels in Tregs present a novel
approach to restore Treg function in GPA patients and potentially
in those with other autoimmune diseases in which there is a
functional defect in the Treg subset.
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